SCHEMBL4436848

SCHEMBL4436848

Cc1nc2c(C(=O)O)cnn2cc1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.48
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 3/20 0.47
HPGD P15428 2/20 0.47
LMNA P02545 4/20 0.43
TP53 P04637 3/20 0.43
MAPT P10636 2/20 0.43
TSHR P16473 3/20 0.40
HIF1A Q16665 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
PTPN1 P18031 3/20 0.40
PTPN2 P17706 1/20 0.40
PTPN6 P29350 1/20 0.40
GAA P10253 1/20 0.39
ALKBH1 Q13686 1/20 0.39
PDE2A O00408 2/20 0.38
NR4A3 Q92570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14033191 0.88 ALDH1A1 (0.48) HSD17B10KDM4EALDH1A1HPGDTSHR
SCHEMBL18208732 0.77 GABRP (0.44) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL14033897 0.77 PDE2A (0.41) HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10696311 0.75 KDM4E (0.45) HSD17B10KDM4EALDH1A1HPGDTP53
SCHEMBL31560164 0.75 ALDH1A1 (0.43) KDM4EALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL4941774 0.74 HSD17B10 (0.83) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL15262396 0.73 HSD17B10 (0.66) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL14033386 0.72 KDM4E (0.56) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL22520960 0.70 POLB (0.51) HSD17B10KDM4EALDH1A1HPGDLMNA
SCHEMBL4941655 0.68 KDM4E (0.79) HSD17B10KDM4EALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137187-A1 PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE Inovacia AB (SE) 2009-12-30 EP disclosed
US-20080255153-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-10-16 US disclosed
US-20080255153-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-10-16 US disclosed
WO-2008116898-A1 PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE BIOVITRUM AB (PUBL) (SE) 2008-10-02 WO disclosed
WO-2008116898-A1 PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE BIOVITRUM AB (PUBL) (SE) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255153-A1 New compounds SCD, SCD5, FADS2 HSD17B10 67/4885KDM4E 1192/4885ALDH1A1 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.